法国多中心研究:儿童可乐定用药错误特征分析
该回顾性观察研究分析了1985年至2024年6月法国药物警戒与中毒控制中心数据库中12岁以下儿童可乐定相关用药错误,共91例。多数错误发生在医院给药阶段(73%),超10倍处方剂量暴露最常见(52%),常因成人制剂错误调整用于儿童所致。87例超暴露中63例(72%)出现心动过缓、低血压或嗜睡等临床表现。
要点
- 儿童可乐定用药错误多发生在医院给药阶段,超10倍剂量暴露占52%。
- 87例超暴露中72%出现心动过缓、低血压或嗜睡等临床表现。
- 缺乏儿童专用制剂和按体重给药困难是主要错误诱因。
核心结论
- 儿童可乐定用药错误主要与医院给药环节挑战相关,缺乏儿童制剂加剧了风险。
- 需通过监管改革、开发即用型儿童制剂和标准化给药方案来提升用药安全。
研究设计与样本
- 回顾性观察研究,分析1985年至2024年6月法国药物警戒与中毒控制中心数据库中12岁以下儿童可乐定相关用药错误报告。
- 共纳入91例病例,采用描述性统计分析常见模式和风险因素。
主要发现
- 多数错误发生在医院给药阶段(73%)。
- 超10倍处方剂量暴露最常见(52%),常因成人制剂错误调整用于儿童所致。
- 87例超暴露中41例(47%)接受预防性干预如活性炭,63例(72%)出现心动过缓、低血压或嗜睡等临床表现。
- 63例出现临床表现的患儿中20例(32%)接受治愈性治疗,包括液体支持(n=10;50%)、阿托品(n=6;30%)和纳洛酮(n=6;30%)。
临床怎么用
- 临床给药时应严格按体重计算儿童可乐定剂量,避免直接套用成人制剂调整。
- 医院给药环节应加强核对,警惕超10倍剂量暴露风险。
- 对超暴露患儿应评估预防性干预指征,并监测心动过缓、低血压和嗜睡等表现。
局限性
- 本研究为回顾性观察研究,数据来源于药物警戒与中毒控制中心报告,可能存在报告偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: This study aimed to describe the characteristics of medication errors involving clonidine in paediatric patients and reported to French Network of Pharmacovigilance and Poison Control Centres. METHODS: This retrospective observational study analysed clonidine-related medication errors reported between 1985 and June 2024 in patients under 12 years. Data were extracted from both the French Pharmacovigilance and Poison Control Centres databases. Descriptive statistics were applied to identify common patterns and risk factors. RESULTS: A total of 91 cases were analysed. Most errors occurred during the administration stage in hospital settings (73%). Overexposure exceeding 10 times the prescribed dose was the most frequent (52%), often resulting from the erroneous adaptation of adult formulations for paediatric use. Among 87 cases of overexposure, 41 children (47%) received preventive interventions (e.g., activated charcoal) and 63 (72%) experienced clinical manifestations such as bradycardia, hypotension or somnolence. Among them, 20 (32%) received curative treatment such as fluid support (n = 10; 50%), atropine (n = 6; 30%) and naloxone (n = 6; 30%) administration. Challenges in weight-based dosing and the lack of paediatric-specific formulations were identified as significant contributors to errors. CONCLUSIONS: Medication errors involving clonidine in paediatric patients are predominantly linked to challenges during hospital administration, exacerbated by the absence of paediatric formulations. Addressing these risks requires regulatory changes, including the development of ready-to-use paediatric formulations and standardized dosing protocols, to enhance clonidine safety in clinical practice.
引用
- Thillard EM, Facile A, Lepelley M, et al. Paediatric clonidine medication errors: Findings from a multicentre French study. Br J Clin Pharmacol. 2026. PMID: 42637235. doi:10.1002/bcp.70797
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。